LOS ANGELES – (BUSINESS WIRE) – August 4, 2021–
Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced that the six facial products of the Seratopic revolution The skincare line will be available for purchase from CVS in the fall of 2021. CVS is one of America’s leading national drugstore chains.
Seratopic revolution marries nature and science in a line of clean and nourishing beauty products. The range’s P3P complex, developed by CURE Pharmaceutical, injects natural, clean, herbal ingredients into the deep layers of the skin using a proprietary tri-peptide delivery system. Unlike other companies that use alcohol as their delivery system, which dries out the skin incredibly, Seratopic revolution natural oil and surfactant delivery systems are very effective and provide almost immediate results.
Nancy Duitch, CEO of Sera Labs and Strategic Director of CURE Pharmaceutical, said: âThere are many beauty companies out there, but the problem is most of them don’t understand that without an effective distribution system, products are on top of your skin and clog your pores. Our formulators have developed a proprietary high-tech delivery system that allows ingredients to penetrate deep into the skin. Our loyal customers will benefit from scientifically proven ingredients that are designed to improve hydration and rejuvenate collagen. Our Seratopic revolution facial products have these unique problem-solving attributes associated with beautiful packaging that stands out on the shelves and our partnership with one of the world’s most respected and recognized players: Nicole Kidman – as a strategic partner and Global Brand Ambassador – making our company and brand a fierce competitor in the beauty industry.
âThis is another fantastic branding and expansion opportunity for our company and its product line. We created Seratopic revolution to meet the needs of a broad customer base, for all people of all skin types looking to explore truly innovative and cutting edge skin care product options. The fact that our skincare line is available at CVS for customers to buy strengthens our national presence and demonstrates the ever-growing support of retailers, âsaid John Cammarano, senior vice president of marketing and sales at Sera. Labs.
Cammarano continued, âWe have just started building our successful brand by leveraging multiple marketing channels that will not only build brand awareness, but always focus on ROI. Since there are many beauty companies available for retailers, we are delighted that CVS has given the Seratopic revolution product line a prime location for storage space and our products will reside between two of the world’s most recognized brands, giving our company the opportunity to acquire new customers and drive sales.
CVS is the leading retail pharmacy in the United States with nearly 10,000 locations, including more than 1,700 pharmacies within Target and Schnucks grocery stores. We are committed to providing innovative healthcare solutions that create a simpler and more accessible experience for patients, clients and caregivers. CVS is the only national pharmacy to remove tobacco products from its shelves and has played a leadership role in the response to the COVID-19 pandemic by making testing and vaccinations available in locations across the United States. For the latest product and service offerings, visit www.cvs.com or download the CVS Pharmacy app.
About Sera Labs
Sera Labs Â® is a trusted leader in the health, wellness and beauty industries of innovative products with cutting edge technology and superior ingredients such as CBD and clean herbal products. Sera Labs creates high quality products that use proprietary formulations based on science. Its more than 20 products are sold under the Seratopical â¢ brands, and SeraLabs â¢, Sera Labs sells its products at affordable prices, making them easily accessible globally. Strategically positioned in the growing beauty, health and wellness market categories. Sera Labs products are sold through major national pharmaceutical chains, grocery chains and mass retailers. The company also sells private label products to major retailers and multi-tier merchants, as well as consumer direct (DTC), through online orders on the website, including opt-in subscriptions. For more information visit: Seratopicalrevolution.com, Seratopical.com, Seralabshealth.com and follow us on Instagram at @seratopical, as well as Twitter, and Facebook. Media contact: firstname.lastname@example.org.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical Â® is the pioneering developer of CUREform â¢, a patented drug delivery platform that offers a number of unique immediate and controlled release drug delivery vehicles designed to improve efficacy, safety and effectiveness. patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot FDA registered and NSFÂ® cGMP certified manufacturing facility enables it to partner with pharmaceutical and wellness companies around the world to a private and white label production. CURE has partnerships in the United States, China, Mexico, Canada, Israel and other markets in Europe.
Statements that CURE makes in this press release may include statements that are not historical fact and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (âSecurities Actâ), and of Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are generally identified by the use of words such as “anticipates”, “believes”, “believes”, “expects” to “,” intends to “,” may “,” “”, “plans”, “research”, “should”, “will” and variations of these words or similar expressions. CURE intends that such forward-looking statements be covered by the Safe Harbor for Forward-Looking Statements provisions contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for the purpose of comply with these Safe Harbor provisions.
These forward-looking statements include, without limitation, the ability to successfully market the products in partnership, the difficulty of predicting the timing or outcome of related research and development efforts, the characteristics and indications of the products in partnership, the authorizations marketing and launches of other products, the impact of regulation of the pharmaceutical industry, the impact of competitive products and prices, the acceptance and demand of new pharmaceuticals, the impact of patents and others property rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements contained in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intention or obligation to update these forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of our securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. prior to registration or qualification under the securities laws of any such state or jurisdiction.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20210804005409/en/
CONTACT: Media contact:
Monica M. Jaramillo, LABEL The Agency, mjaramillo @ labeltheagency.com Investor contact:
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: COSMETICS SUPERMARKET DETAIL SPECIALTY
SOURCE: Pharmaceutical CURE
Copyright Business Wire 2021.
PUB: 08/04/21 07: 00 / DISC: 08/04/21 07:02